1
|
Silva FS, de Souza KSC, Galdino OA, de Moraes MV, Ishikawa U, Medeiros MA, Lima JPMS, de Paula Medeiros KC, da Silva Farias NB, de Araújo Júnior RF, de Rezende AA, Abreu BJ, de Oliveira MF. Hyperbaric oxygen therapy mitigates left ventricular remodeling, upregulates MMP-2 and VEGF, and inhibits the induction of MMP-9, TGF-β1, and TNF-α in streptozotocin-induced diabetic rat heart. Life Sci 2022; 295:120393. [PMID: 35167880 DOI: 10.1016/j.lfs.2022.120393] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2021] [Revised: 02/02/2022] [Accepted: 02/06/2022] [Indexed: 11/17/2022]
Abstract
AIMS Hyperbaric oxygen (HBO) therapy has been widely used for the adjunctive treatment of diabetic wounds, and is currently known to influence left ventricular (LV) function. However, morphological and molecular repercussions of the HBO in the diabetic myocardium remain to be described. We aimed to investigate whether HBO therapy would mitigate adverse LV remodeling caused by streptozotocin (STZ)-induced diabetes. MAIN METHODS Sixty-day-old Male Wistar rats were divided into four groups: Control (n = 8), HBO (n = 7), STZ (n = 10), and STZ + HBO (n = 8). Diabetes was induced by a single STZ injection (60 mg/kg, i.p.). HBO treatment (100% oxygen at 2.5 atmospheres absolute, 60 min/day, 5 days/week) lasted for 5 weeks. LV morphology was evaluated using histomorphometry. Gene expression analyzes were performed for LV collagens I (Col1a1) and III (Col3a1), matrix metalloproteinases 2 (Mmp2) and 9 (Mmp9), and transforming growth factor-β1 (Tgfb1). The Immunoexpression of cardiac tumor necrosis factor-α (TNF-α) and vascular endothelial growth factor (VEGF) were also quantified. KEY FINDINGS HBO therapy prevented LV concentric remodeling, heterogeneous myocyte hypertrophy, and fibrosis in diabetic rats associated with attenuation of leukocyte infiltration. HBO therapy also increased Mmp2 gene expression, and inhibited the induction of Tgfb1 and Mmp9 mRNAs caused by diabetes, and normalized TNF-α and VEGF protein expression. SIGNIFICANCE HBO therapy had protective effects for the LV structure in STZ-diabetic rats and ameliorated expression levels of genes involved in cardiac collagen turnover, as well as pro-inflammatory and pro-angiogenic signaling.
Collapse
Affiliation(s)
- Flávio Santos Silva
- Department of Health Sciences, Federal Rural University of the Semi-Arid, Mossoró, Brazil.
| | | | - Ony Araujo Galdino
- Department of Clinical and Toxicological Analysis, Federal University of Rio Grande do Norte, Natal, Brazil
| | | | - Uta Ishikawa
- Department of Morphology, Federal University of Rio Grande do Norte, Natal, Brazil
| | | | | | | | | | | | - Adriana Augusto de Rezende
- Department of Clinical and Toxicological Analysis, Federal University of Rio Grande do Norte, Natal, Brazil
| | - Bento João Abreu
- Department of Morphology, Federal University of Rio Grande do Norte, Natal, Brazil
| | | |
Collapse
|
2
|
de Almeida Júnior RF, de Souza KSC, Galdino OA, da Silva Junior AA, Arrais RF, Machado PRL, Farias KJS, de Rezende AA. Chloroquine as a promising adjuvant therapy for type 1 Diabetes Mellitus. Sci Rep 2020; 10:12098. [PMID: 32694530 PMCID: PMC7374610 DOI: 10.1038/s41598-020-69001-2] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2020] [Accepted: 07/03/2020] [Indexed: 11/09/2022] Open
Abstract
Chloroquine (CQ) and hydroxychloroquine, are promising anti-inflammatory drugs for the treatment of Diabetes mellitus (DM) to prevent associated complications. Therefore, this study evaluated the anti-inflammatory effects of CQ-free and CQ-incorporated polylactic acid nanoparticles (NPs) in the peripheral blood mononuclear cells (PBMCs) of patients with type 1 Diabetes mellitus (T1DM). In total, 25 normoglycemic individuals and 25 patients with T1DM aged 10-16 years were selected and glycemic controls evaluated. After cell viability assessed by MTT assay, T1DM PBMCs were subjected to a CQ concentration of 10 µM in three different conditions: not treated (NT), treated with CQ, and treated with CQ NPs. The cells were incubated for 48 h, and the mRNA expressions of cytokines IL1B, IFNG, TNFA, IL12, and IL10 were determined by relative quantification through real-time PCR at 24 h intervals. IL1B expression decreased in CQ and CQ NP-treated cells after 48 h (p < 0.001) and 24 h (p < 0.05) of treatment, respectively. IFNG and IL12 expressions significantly decreased (p < 0.001) in cells treated with CQ and CQ NPs at 24 and 48 h compared to NT. TNFA and IL10 expressions significantly decreased after 48 h (p < 0.001) and 24 h (p < 0.002), respectively, by both CQ and CQ NPs treatment. Despite being a preliminary in vitro study, CQ has anti-inflammatory activity in the primary cells of T1DM patients and could represent an alternative and adjuvant anti-inflammatory therapy to prevent diabetes complications.
Collapse
Affiliation(s)
- Renato Ferreira de Almeida Júnior
- Department of Clinical and Toxicological Analyses, Federal University of Rio Grande Do Norte (UFRN), Av. General Gustavo Cordeiro de Farias, S/N, Faculdade de Farmácia, Petrópolis, Natal, RN, CEP: 59012-570, Brazil
| | - Karla Simone Costa de Souza
- Department of Clinical and Toxicological Analyses, Federal University of Rio Grande Do Norte (UFRN), Av. General Gustavo Cordeiro de Farias, S/N, Faculdade de Farmácia, Petrópolis, Natal, RN, CEP: 59012-570, Brazil
| | - Ony Araujo Galdino
- Department of Clinical and Toxicological Analyses, Federal University of Rio Grande Do Norte (UFRN), Av. General Gustavo Cordeiro de Farias, S/N, Faculdade de Farmácia, Petrópolis, Natal, RN, CEP: 59012-570, Brazil
| | | | - Ricardo Fernando Arrais
- Department of Pediatrics, Pediatric Endocrinology Unit, Federal University of Rio Grande Do Norte, (UFRN), Natal, RN, 59012-570, Brazil
| | - Paula Renata Lima Machado
- Department of Clinical and Toxicological Analyses, Federal University of Rio Grande Do Norte (UFRN), Av. General Gustavo Cordeiro de Farias, S/N, Faculdade de Farmácia, Petrópolis, Natal, RN, CEP: 59012-570, Brazil
| | - Kleber Juvenal Silva Farias
- Center of Education and Health, Federal University of Campina Grande, Campina Grande, PB, 58175-000, Brazil.
| | - Adriana Augusto de Rezende
- Department of Clinical and Toxicological Analyses, Federal University of Rio Grande Do Norte (UFRN), Av. General Gustavo Cordeiro de Farias, S/N, Faculdade de Farmácia, Petrópolis, Natal, RN, CEP: 59012-570, Brazil.
| |
Collapse
|